Is Spectrum Pharma Getting Enough for Its Hematology/Oncology Portfolio?
Spectrum Pharmaceuticals on Thursday after the firm announced that it would be selling its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma.
Spectrum Pharmaceuticals on Thursday after the firm announced that it would be selling its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma.
The December 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
CVS shares dipped on Tuesday after the company announced that it would be parting ways with the megastore Walmart.
Aptinyx shares were absolutely crushed on Wednesday after the firm reported midstage results from its clinical study in patients with painful diabetic peripheral neuropathy.
CVS shares dipped on Tuesday after the company announced that it would be parting ways with the megastore Walmart.
The December 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The December 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The 2018-2019 flu season is predicted to cost U.S. businesses some $17 billion in lost productivity. Here are some steps employees and employers can take to minimize the impact.
Akorn shares dipped on Wednesday after the company received a warning letter from the FDA regarding its Decatur, Illinois, manufacturing facility.
Moderna shares made a handy gain early Tuesday after the company announced updates to several of its immuno-oncology and rare disease programs and outlined its 2019–2020 corporate objectives.
Clinical-stage biopharmaceutical company Alector has filed with the SEC for its initial public offering.
Loxo shares made a massive gain on Monday after it was announced that the firm would be acquired by Eli Lilly. The transaction is not subject to any financing condition and is expected to…
Axsome shares absolutely exploded on Monday after the company announced that its midstage trial in patients with major depressive disorder met its primary endpoint.
Clinical-stage biopharmaceutical company Poseida Therapeutics has filed with the SEC regarding its initial public offering.
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the first quarter of 2019.